Skip to main content

Table 4 Cumulative incidence rates of serious infections per 100 patient-years in psoriasis patients with self-reported PsA enrolled in PSOLAR; By cohort

From: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

 UstekinumabTNF inhibitorsaInfliximabEtanerceptAdalimumabNon-biologic/MTXbNon-biologic/non-MTXcAlld
Overall population
 N6281413258481674982082401
 PY20094101756143219133666947244
 Serious infections and infestations1.00 [20]2.22 [91]2.12 [16]2.58 [37]1.99 [38]3.01 [11]2.31 [16]1.91 [138]
Incident population
 N32648664130292982081163
 PY90410821252916653666943101
 Serious infections and infestations0.88 [8]2.50 [27]0.80 [1]3.09 [9]2.56 [17]3.01 [11]2.31 [16]2.00 [62]
Bionaive population
 N5616714728198208532
 PY144419351802043666941626
 Serious infections and infestations1.39 [2]1.91 [8]0.00 [0]3.33 [6]0.98 [2]3.01 [11]2.31 [16]2.28 [37]
  1. Data are incidence rate [n]
  2. The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
  3. The incidence of adverse events is reported as rate of adverse events per 100 PY. Number of PY is defined as the number of years exposed to the cohort defining medication. Exposure starts from first exposure to a medication on\during registry participation and ends at the earlier of the date of reference end date, initiating another biologic/medication, 90 days after the last dose of the cohort defining treatment, or the date of the annual data cutoff (23AUG2016), whichever is sooner.
  4. PY = number of days exposed / 365.25
  5. MTX methotrexate; PsA psoriatic arthritis; PSOLAR Psoriasis Longitudinal Assessment and Registry; PY patient-years
  6. aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
  7. bThe non-biologic/MTX cohort includes patients who are receiving MTX at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
  8. cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are receiving other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who receive only topical and/or phototherapy at/after registry entry are also in this cohort
  9. dIncludes “Other biologics” group (n = 54); data not shown